Skip to content

Quality of adherence to guideline recommendations for life-saving treatment in heart failure: an international survey

QUAlity of adherence to guideline recommendations for LIfe-saving treatment in heart failure: an international surveY: an observational study

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
ISRCTN
Registry ID
ISRCTN87465420
Enrollment
7092
Registered
2015-05-07
Start date
2013-09-01
Completion date
Unknown
Last updated
2023-06-26

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Heart failure Circulatory System Heart disease

Interventions

Non-interventional survey

Sponsors

Servier
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: Outpatients with chronic heart failure: 1. > 18 years of age 2. Hospitalised for worsening of heart failure within 1–15 months 3. With LVSD as demonstrated by left ventricular ejection fraction = 40% measured using the most recent echocardiogram (= 2 years) 4. Validation of rhythm at inclusion

Exclusion criteria

Exclusion criteria: 1. Patients on waiting list for heart transplantation or planned implantation of left ventricular assist device; planned cardiac resynchronisation therapy and implantable cardioverter defibrillators are permitted 2. Patients with planned revascularisation 3. Patients hospitalised for cardiovascular disease within the past 4 weeks 4. Conditions hampering participation or the 18-month follow-up

Design outcomes

Primary

MeasureTime frame
1 To evaluate physician’s adherence to HF guidelines by measuring prescriptions modalities of recommended HF medications 2. To calculate an adherence score 3. To analyze the reasons for non-adherence 4. To assess the impact of adherence level on clinical outcomes Measured at baseline and at 6, 12 and 18 months.

Secondary

MeasureTime frame
To characterize the clinical characteristics and management of outpatients with HF and left ventricular systolic dysfunction (LVSD). Measured at baseline and at 6, 12 and 18 months.

Countries

Armenia, Australia, Austria, Azerbaijan, Bahrain, Belarus, Brunei, Canada, China, Denmark, Egypt, Georgia, Germany, Greece, Hungary, Ireland, Jordan, Kazakhstan, Korea, South, Kuwait, Lebanon, Lithuania, Malaysia, Morocco, Oman, Poland, Portugal, Qatar, Romania, Russian Federation, Slovakia, Spain, Thailand, Turkey, Ukraine, United Arab Emirates

Outcome results

None listed

Source: ISRCTN (via WHO ICTRP) · Data processed: Feb 4, 2026